CN106581641B - 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 - Google Patents
一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 Download PDFInfo
- Publication number
- CN106581641B CN106581641B CN201611242453.0A CN201611242453A CN106581641B CN 106581641 B CN106581641 B CN 106581641B CN 201611242453 A CN201611242453 A CN 201611242453A CN 106581641 B CN106581641 B CN 106581641B
- Authority
- CN
- China
- Prior art keywords
- reperfusion injury
- myocardial ischemia
- polypeptide
- preventing
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 34
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 26
- 201000010099 disease Diseases 0.000 title claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000498253 Ancylostoma duodenale Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- VLIJYPMATZSOLL-YUMQZZPRSA-N Gly-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VLIJYPMATZSOLL-YUMQZZPRSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- BYEBKXRNDLTGFW-CIUDSAMLSA-N Lys-Cys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O BYEBKXRNDLTGFW-CIUDSAMLSA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- YUGFLWBWAJFGKY-BQBZGAKWSA-N Arg-Cys-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O YUGFLWBWAJFGKY-BQBZGAKWSA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- MHBUWPFQNPJTAS-QAETUUGQSA-N Asn-Leu-Phe-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=CC=C1 MHBUWPFQNPJTAS-QAETUUGQSA-N 0.000 description 1
- GFGUPLIETCNQGF-DCAQKATOSA-N Asn-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O GFGUPLIETCNQGF-DCAQKATOSA-N 0.000 description 1
- LKIYSIYBKYLKPU-BIIVOSGPSA-N Asp-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O LKIYSIYBKYLKPU-BIIVOSGPSA-N 0.000 description 1
- IAMNNSSEBXDJMN-CIUDSAMLSA-N Asp-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N IAMNNSSEBXDJMN-CIUDSAMLSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- KJJASVYBTKRYSN-FXQIFTODSA-N Cys-Pro-Asp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CC(=O)O)C(=O)O KJJASVYBTKRYSN-FXQIFTODSA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- TWYSSILQABLLME-HJGDQZAQSA-N Glu-Thr-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYSSILQABLLME-HJGDQZAQSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- SUDUYJOBLHQAMI-WHFBIAKZSA-N Gly-Asp-Cys Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O SUDUYJOBLHQAMI-WHFBIAKZSA-N 0.000 description 1
- BIRKKBCSAIHDDF-WDSKDSINSA-N Gly-Glu-Cys Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BIRKKBCSAIHDDF-WDSKDSINSA-N 0.000 description 1
- HFXJIZNEXNIZIJ-BQBZGAKWSA-N Gly-Glu-Gln Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFXJIZNEXNIZIJ-BQBZGAKWSA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- STWGDDDFLUFCCA-GVXVVHGQSA-N His-Glu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O STWGDDDFLUFCCA-GVXVVHGQSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- MSSJJDVQTFTLIF-KBPBESRZSA-N Lys-Phe-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O MSSJJDVQTFTLIF-KBPBESRZSA-N 0.000 description 1
- HONVOXINDBETTI-KKUMJFAQSA-N Lys-Tyr-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CC=C(O)C=C1 HONVOXINDBETTI-KKUMJFAQSA-N 0.000 description 1
- PPNCMJARTHYNEC-MEYUZBJRSA-N Lys-Tyr-Thr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 PPNCMJARTHYNEC-MEYUZBJRSA-N 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- OJUMUUXGSXUZJZ-SRVKXCTJSA-N Phe-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OJUMUUXGSXUZJZ-SRVKXCTJSA-N 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 1
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 1
- CWVHKVVKAQIJKY-ACRUOGEOSA-N Tyr-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=C(C=C2)O)N CWVHKVVKAQIJKY-ACRUOGEOSA-N 0.000 description 1
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- -1 calcium antagonists Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002530 ischemic preconditioning effect Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010411 postconditioning Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的应用，属于生物医药领域。该多肽氨基酸序列为：SEQ ID NO.1或SEQ ID NO.2。本发明中的多肽能显著减少心肌缺血再灌注损伤中的心肌梗死面积，可作为预防或治疗心肌缺血再灌注损伤相关疾病的药物，具有临床应用价值。
Description
技术领域
本发明涉及生物医药领域，具体地说本发明涉及一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的应用。
背景技术
心肌缺血引起的心脏病，即缺血性心脏病，亦称冠心病，临床常见且危害严重，其中心肌梗死(myocardial infarction,MI)是心肌缺血心脏病中危害最大、最致命的一种，致死率很高。通过恢复缺血心肌血流(再灌注)是治疗心肌缺血最有效的措施，但是再灌注本身可导致复杂的病理生理反应，加重心肌损伤，引起心肌缺血再灌注损伤(myocardialischemia reperfusion injury,MIRI)。目前，临床上应用抗氧化治疗、腺苷受体激动剂、钙拮抗剂、Na+/H+、Na+/Ca2+离子交换抑制剂、缺血预适应、后适应处理、他汀类、β受体阻滞剂、抗血小板聚集剂等探索性地治疗MIRI，但临床疗效并不能令人满意[徐盟.心肌缺血再灌注损伤的主要机制与相关药物治疗的研究进展.实用药物与临床.2014；17(8):1052-1055；彭军,李元建.第十九章抗心肌缺血药//苏定冯,陈丰原主编.心血管药理学(第4版).北京:人民卫生出版社.2011年,P401-417]。目前，国外正在进行应用环孢素A(Cyclosporine-A)、美托洛尔(metoprolol)、阿昔单抗(abciximab)和艾塞那肽(Exenatide)等药物治疗MIRI的临床II期研究[
B,et al.Evolving therapies for myocardial ischemia/reperfusion injury.J Am Coll Cardiol.2015；65(14):1454-1471]。虽然目前用于防治MIRI药物虽有一定疗效，但却十分有限。
发明内容
本发明要解决的问题是提供一种抗心肌缺血再灌注损伤的多肽药物的应用，以减少或避免引起心肌缺血再灌注损伤。
为减少或避免引起心肌缺血再灌注损伤，本发明提供了一种多肽AdKI4的完整氨基酸序列或其突变体在抗心肌缺血再灌注损伤相关疾病中的药物应用。AdKI4的完整氨基酸序列为：SEQ ID NO.1，或AdKI4的突变体，如在完整氨基酸的氨基端或羧基端缺失一个或多个氨基酸残基后形成的突变体，如氨基酸序列：SEQ ID NO.2。
本发明通过药理实验证实了AdKI4能明显减少心肌缺血再灌注后的心肌梗死面积，有效减轻心肌缺血再灌注损伤，因此，该多肽可应用于预防或治疗心肌缺血再灌注损伤相关疾病，如心肌梗死、冠心病等，有广泛的临床应用价值。
附图说明
以下附图仅旨在于对本发明做示意性说明和解释，并不限定本发明的范围。其中，
图1显示的是AdKI4对心肌缺血再灌注损伤心肌梗死率的影响(n＝8)。
图2显示的是心脏切片示AdKI4对SD大鼠心肌缺血再灌注损伤心肌梗死面积的影响(NBT染色，灰白色区域为心肌梗死区)。A.对照组(假手术组)；B.低剂量组(1.0mg/kg﹒BW)；C.中剂量组(2.0mg/kg﹒BW)；D.高剂量组(4.0mg/kg﹒BW)。BW为体重。
具体实施方式
为了对本发明的技术特征、目的和效果有更加清楚的理解，现对照附图说明本发明的具体实施方式。以下具体实施例仅用于说明本发明而不用于限制本发明的范围。
本发明人前期在十二指肠钩虫(Ancylostoma duodenale)中分离到一种多肽-AdKI4。发明人通过系列探索研究，利用SD大鼠心肌缺血再灌注损伤模型，首先明确了AdKI4能明显减少心肌缺血再灌注后的心肌梗死面积，并呈剂量依赖关系，表明AdKI4对缺血再灌注心肌损伤具有很好保护作用，因此，AdKI4可作为药物应用于预防或治疗心肌缺血再灌注损伤相关疾病。
实施例rAdKI4对心肌缺血再灌注损伤的保护作用
1实验材料
重组AdKI4(rAdKI4)由发明人在实验室重组制备，纯度大于95％；SPF级SD大鼠购自广东省医学实验动物中心[实验动物证：SCXK(粤)2013-0002；SYXK(粤)2012-0122]；氯化硝基四氮唑蓝(Tetranitroblue tetrazolium chloride，NBT)为Sigma公司产品。
2实验方法
2.1动物分组：体重180～250g的SPF级SD大鼠40只，随机分为5组，每组8只，分别为：空白对照组(假手术组)、模型组、rAdKI4高剂量组(4.0mg/kg﹒BW)、中剂量组(2.0mg/kg﹒BW)、低剂量组(1.0mg/kg﹒BW)。BW为体重(body weight，BW)。
实验获得AdKI4的完整氨基酸序列为：SEQ ID NO.1，或AdKI4的突变体，如SEQ IDNO.2，是在SEQ ID NO.1氨基端缺失7个氨基酸残基、羧基端缺失3个氨基酸残基的序列。
2.2构建模型及给药：
(1)SD大鼠心肌缺血再灌注(I/R)模型构建：异氟烷呼吸麻醉机麻醉大鼠，仰卧固定，37℃维持体温，气管插管，连接小动物呼吸机辅助呼吸(吸呼比＝1:1，呼吸频率＝80次/min，潮气量＝4.0ml)，经胸骨左缘第2～3肋间打开胸腔，用开睑器轻轻拉开开口，暴露心脏，剪开心包膜，找到左心耳和肺动脉圆锥，在左心耳根部下方2mm处以4-0线进针，穿过心肌表层在肺动脉圆锥处稍下方出针，中间放一已消毒1cm长的棉线，结扎冠状动脉前降支(LAD)，合上并排除胸腔空气，缺血30min，显微剪剪断结扎线，再灌注24h；空白对照组(假手术组)只穿线不结扎。动物缺血前及缺血后记录心电图。
(2)给药：药物组于缺血前2min内尾静脉注射给药，空白对照组和模型组于缺血前2min内尾静脉注射给予等量生理盐水。
2.3心肌梗死面积测量：再灌注24h后，异氟烷呼吸麻醉实验大鼠，取出心脏后，生理盐水冲洗干净，于-20℃冰冻30min，于心脏结扎处向下横切片(2mm/片)，37℃下，氯化硝基四氮唑蓝液(NBT)染色30min，扫描仪扫描并计算梗死面积。梗死率＝心肌梗死区面积/心肌面积
2.4统计方法：用SPSS16.0软件包进行统计分析，数据用均数±标准差
表示。3组之间比较用单因素方差分析(ANOVA)，两两比较用q检验，以P<0.05为差异有统计学意义。
3实验结果
AdKI4能显著减少心肌缺血再灌注损伤心肌梗死面积(图2)。与模型组比较，AdKI4各组均显著减少心肌梗死率(P<0.05)，且高、中、低剂量组减少心肌梗死率呈明显剂量依赖关系(P<0.05)(表1，图1)。
表1重组AdKI4对SD大鼠心肌梗死率的影响(n＝8)
注：*与模型组比较，P<0.05；#高、中、低剂量组比较，P<0.05
4结论：AdKI4对心肌缺血再灌注损伤具有显著保护作用，且呈剂量依赖关系，可作为药物应用于预防或治疗心肌缺血再灌注损伤相关疾病。
以上所述仅为本发明示意性的具体实施方式，并非用以限定本发明的范围。任何本领域的技术人员，在不脱离本发明的构思和原则的前提下所作的等同变化、修改与结合，均应属于本发明保护的范围。
<110> 广东医科大学
<120> 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用
<160> 2
<210> 1
<211> 61
<212> PRT
<213> 十二指肠钩虫Ancylostoma duodenale
<400> 1
Asn Pro His Arg Lys Gly Arg Cys Gly Asp Asp Pro Ala Glu Thr
1 5 10 15
Gly Gly Glu Cys Pro Asp Pro Glu Thr Lys Tyr Thr Tyr Lys Phe
20 25 30
Gly Asp Cys His Glu Val Lys Tyr Cys Gly Glu Gln Glu Thr Arg
35 40 45
Asn Leu Phe Asp Ser Tyr Glu Lys Cys Ser Gly Lys Cys Val Ile
50 55 60
Phe
<210> 2
<211> 51
<212> PRT
<213> 十二指肠钩虫Ancylostoma duodenale
<400> 2
Cys Gly Asp Asp Pro Ala Glu Thr Gly Gly Glu Cys Pro Asp Pro
1 5 10 15
Glu Thr Lys Tyr Thr Tyr Lys Phe Gly Asp Cys His Glu Val Lys
20 25 30
Tyr Cys Gly Glu Gln Glu Thr Arg Asn Leu Phe Asp Ser Tyr Glu
35 40 45
Lys Cys Ser Gly Lys Cys
50
Claims (2)
1.一种多肽在制备预防或治疗心肌缺血再灌注损伤相关疾病药物中的应用，该多肽氨基酸序列为：SEQ ID NO.1或SEQ ID NO.2。
2.如权利要求1所述的应用，其中所述心肌缺血再灌注损伤相关疾病为心肌梗死或冠心病。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611242453.0A CN106581641B (zh) | 2016-12-29 | 2016-12-29 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
| PCT/CN2017/118161 WO2018121457A1 (zh) | 2016-12-29 | 2017-12-25 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611242453.0A CN106581641B (zh) | 2016-12-29 | 2016-12-29 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106581641A CN106581641A (zh) | 2017-04-26 |
| CN106581641B true CN106581641B (zh) | 2020-08-07 |
Family
ID=58603259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611242453.0A Active CN106581641B (zh) | 2016-12-29 | 2016-12-29 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106581641B (zh) |
| WO (1) | WO2018121457A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581641B (zh) * | 2016-12-29 | 2020-08-07 | 广东医科大学 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
| CN107536869A (zh) * | 2017-08-28 | 2018-01-05 | 广东医科大学附属医院 | 一种预防心肌缺血再灌注损伤相关疾病的药物组合物及其制备方法 |
| CN107693777B (zh) * | 2017-11-28 | 2020-07-31 | 广东医科大学 | 一种多肽在预防或治疗急性肺损伤相关疾病中的药物应用 |
| CN107929714B (zh) * | 2017-12-01 | 2020-12-25 | 广东医科大学 | 一种多肽在预防或治疗脑缺血再灌注损伤相关疾病中的应用 |
| CN112168952A (zh) * | 2020-10-27 | 2021-01-05 | 成都市妇女儿童中心医院 | 水凝胶搭载环孢素a在制备治疗心肌缺血再灌注损伤的药物中的应用 |
| CN113702645A (zh) * | 2021-08-30 | 2021-11-26 | 复旦大学附属中山医院 | Sirt4在心血管疾病治疗中的用途 |
| CN114249837B (zh) * | 2021-12-28 | 2023-10-20 | 徐州医科大学 | 一种多肽、及其制备方法和应用 |
| CN114262384B (zh) * | 2021-12-28 | 2023-12-26 | 徐州医科大学 | 一种多肽及其保护心肌缺血/再灌注损伤作用的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041072A (zh) * | 2006-03-23 | 2007-09-26 | 吉林圣元科技有限责任公司 | 蛋白酶抑制剂的心肌细胞保护功能及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795954A (en) * | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
| AU1924101A (en) * | 1999-11-22 | 2001-06-04 | Human Genome Sciences, Inc. | Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| US20020102703A1 (en) * | 1999-12-29 | 2002-08-01 | Sheppard Paul O. | Kunitz domain polypeptide zkun10 |
| CN106581641B (zh) * | 2016-12-29 | 2020-08-07 | 广东医科大学 | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 |
-
2016
- 2016-12-29 CN CN201611242453.0A patent/CN106581641B/zh active Active
-
2017
- 2017-12-25 WO PCT/CN2017/118161 patent/WO2018121457A1/zh active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041072A (zh) * | 2006-03-23 | 2007-09-26 | 吉林圣元科技有限责任公司 | 蛋白酶抑制剂的心肌细胞保护功能及应用 |
Non-Patent Citations (1)
| Title |
|---|
| Kunitz type serine protease inhibitor 4 [Ancylostoma duodenale]，GenBank：ADZ39079.1;PENG L F等;《GenBank数据库》;20140331;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106581641A (zh) | 2017-04-26 |
| WO2018121457A1 (zh) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106581641B (zh) | 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用 | |
| KR102216381B1 (ko) | 에다라본 및 (+)-2-보르네올의 설하 약학 조성물 | |
| TW201603818A (zh) | 組成物及方法 | |
| WO2007112675A1 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
| PT89835B (pt) | Processo para a preparacao de uma formulacao de relaxina humana | |
| BR112012001491A2 (pt) | composição de preparação externa para pele | |
| WO2008150929A1 (en) | Topical compositions comprising a macromolecule and methods of using same | |
| JP2017513856A5 (zh) | ||
| WO2024160300A1 (zh) | 用于抑制炎症反应、促进血管生成及伤口愈合的组合物及应用 | |
| AU2016272282A1 (en) | Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide | |
| White et al. | An evaluation of the hemostatic effects of hydrophilic, alcohol, and lipophilic extracts of notoginseng | |
| US20230256042A1 (en) | Treatment of Warts | |
| CN107693777B (zh) | 一种多肽在预防或治疗急性肺损伤相关疾病中的药物应用 | |
| WO2020259294A1 (zh) | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 | |
| JP4880845B2 (ja) | Ｇｒｆ含有凍結乾燥薬剤組成物 | |
| KR101095647B1 (ko) | 당단백질 호르몬 조성물 | |
| CN110693882A (zh) | 一种舌下用药物组合物 | |
| CN108096240B (zh) | 一种治疗肺纤维化的中药组合物 | |
| KR102644156B1 (ko) | 피부 상처 또는 화상 치료 작용제 | |
| EP3906934A1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| CN115461356A (zh) | 用于预防或治疗covid-19的肽 | |
| CN106668865B (zh) | 用于治疗脑缺血的药物组合物、制剂及其应用 | |
| CN117083056A (zh) | 包含ghrp-6的药学组合物 | |
| ELS | Drug for postmenopausal osteoporosis gets nod from FDA | |
| Furyk et al. | From Other Journals. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |